Abstract:The KRAS, NRAS, and HRAS genes are frequently mutated in cancer, often at hotspots altering codons 12, 13, and 61. Yet how different RAS isoforms and mutations precisely regulate oncogenic signaling is still largely unknown. For example, the role of mutant RAS in driving overactivation of ERK signaling in cancer has long been elucidated, but its involvement in the oncogenic activation of PI3K is still controversial, and different studies have reported conflicting findings regarding the requirement of RAS for physiological and oncogenic PI3K signaling. One of the reasons for this lack of understanding has been the inability to directly target RAS, which has historically been circumvented through genomic perturbation and murine models. However, these approaches are limited because it is not possible to distinguish between the direct effects of RAS on PI3K and compensatory events that occur as an adaptation to the oncogene. With the discovery of RAS inhibitors, we can now directly interrogate the biological effects of RAS isoforms and hotspot mutations in cancer cells with improved time resolution. Here, we use RM-042, a first-in-class broad-spectrum RAS·GTP inhibitor (RASMULTI(ON)), to characterize the features and therapeutic vulnerabilities of mutant RAS signaling in human cancers. Through a detailed biochemical analysis of the signaling response to RAS and MEK inhibition, we reveal that RAS-mediated oncogenic signaling is largely independent of the mutant RAS isoform, rather depending on the mutant codon. Specifically, RASQ61X is exquisitely sensitive to MAPK pathway inhibition, confers near-complete independence of upstream regulation, and is impaired in its signaling to PI3K/Akt/mTOR. Conversely, RASG12X enables oncogenic signaling to both MAPK and PI3K/Akt/mTOR by amplifying upstream input from receptor tyrosine kinases (RTKs). Simultaneous RAS and RTK inhibition selectively impairs the growth of RASG12X-mutant tumors, irrespective of RAS isoform and tumor type, and we investigate the molecular mechanisms behind this synergistic effect. Additionally, we have generated a genetically modified mouse model (GEMM) harboring liver tumors induced by RASG12D or RASQ61R. In cell lines derived from these respective models, RASG12D but not RASQ61R activates PI3K upon growth-factor stimulation. Furthermore, in this system, RASQ61R is less oncogenic than RASG12D, an effect that can be rescued by the concurrent deletion of PTEN. These findings provide mechanistic insights into how mutant RAS interacts with upstream and downstream partners to maximize oncogenic signaling. Furthermore, our results shed light on the selective pressure driving the emergence of RASQ61X mutations as a mechanism of resistance against RTK inhibition: we show that colorectal cancer cells that acquire RASQ61X mutations to overcome EGFR inhibition become more independent of upstream signaling than those that acquire RASG12X. Citation Format: Michelangelo Marasco, Dinesh Kumar, Riccardo Mezzadra, Wei Luan, Ilinca Aricescu, Rona Yaeger, Vladimir Markov, Yu Zhu, Elisa de Stanchina, Scott Lowe, Sandra Misale, Neal Rosen. Oncogenic signaling and responses to treatment in RAS mutant cancers are mutation-specific [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr B089.

Genetic alterations in HRAS gene in relation to outcome and response to cetuximab in head and neck squamous cell carcinoma.

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors

Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy

Identification and Prognostic Analysis of the Cetuximab Resistance-Related Gene REV1 in RAS Wild-Type Metastatic Colorectal Cancer.

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Prevalence Of K-Ras Codon 12 Mutations In Locally Advanced Head And Neck Squamous Cell Carcinoma And Influence With Regards To Response To Chemoradiation Therapy

KRAS in NSCLC: State of the Art and Future Perspectives

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC

Cooperative genomic lesions in HRAS -mutant cancers predict resistance to farnesyltransferase inhibitors

Abstract 3177: KRAS Gene Status in Gastric Signet-Ring Cell Carcinoma Patients and Act As Biomarker of MEK Inhibitor

Abstract B089: Oncogenic signaling and responses to treatment in RAS mutant cancers are mutation-specific

Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy

K-ras status and efficacy of cetuximab-containing regimen in the treatment of patients with metastatic colorectal cancer

New Arrows in the Quiver

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer

Tumor Genomics and the Association with Survival in Recurrent/metastatic Head and Neck Cancer Patients

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers

Emerging strategies to target RAS signaling in human cancer therapy